GlobeNewswire: Bionano Genomics Contains the last 10 of 308 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T17:54:27ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2023/05/09/2664907/0/en/Bionano-Reports-First-Quarter-2023-Results-and-Highlights-Recent-Business-Progress.html?f=22&fvtc=4&fvtv=51595Bionano Reports First Quarter 2023 Results and Highlights Recent Business Progress2023-05-09T20:01:00Z<![CDATA[SAN DIEGO, May 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2023.]]>https://www.globenewswire.com/news-release/2023/05/01/2658702/0/en/Bionano-Announces-the-Publication-of-Stockholder-Letter-Regarding-Support-for-Proxy-Proposal.html?f=22&fvtc=4&fvtv=51595Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal2023-05-01T23:50:48Z<![CDATA[SAN DIEGO, May 01, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced that on May 1, 2023, it published an open letter to stockholders in support of its proposals at its upcoming annual meeting of stockholders, a copy of which is included at the end of this press release.]]>https://www.globenewswire.com/news-release/2023/04/26/2655004/0/en/Bionano-Announces-Three-Publications-Demonstrating-OGM-s-Utility-for-Hematological-Malignancy-Research.html?f=22&fvtc=4&fvtv=51595Bionano Announces Three Publications Demonstrating OGM’s Utility for Hematological Malignancy Research2023-04-26T12:00:00Z<![CDATA[SAN DIEGO, April 26, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO), today announced the publication of three studies which collectively illustrate the continued development of data supporting optical genome mapping (OGM) as an alternative to traditional cytogenetic methods for the analysis of hematological malignancies. The studies confirm OGM’s high level of concordance and ability to identify relevant variants that are not detected by traditional methods but that could have an impact on clinical research, potentially leading to improved patient management, including therapy selection and overall risk assessment.]]>https://www.globenewswire.com/news-release/2023/04/24/2652839/0/en/UPDATE-Bionano-Announces-Preliminary-Q1-2023-Results-and-Business-Updates.html?f=22&fvtc=4&fvtv=51595UPDATE - Bionano Announces Preliminary Q1 2023 Results and Business Updates2023-04-24T13:54:33Z<![CDATA[SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial results and business updates for the first quarter ended March 31, 2023.]]>https://www.globenewswire.com/news-release/2023/04/24/2652665/0/en/Bionano-Announces-Preliminary-Q1-2023-Results-and-Business-Updates.html?f=22&fvtc=4&fvtv=51595Bionano Announces Preliminary Q1 2023 Results and Business Updates2023-04-24T12:00:00Z<![CDATA[SAN DIEGO, April 24, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported certain unaudited preliminary financial results and business updates for the first quarter ended March 31, 2023.]]>https://www.globenewswire.com/news-release/2023/04/13/2646677/0/en/Bionano-Announces-Presentation-of-OGM-Utility-Across-Cancer-Genomics-Research-Applications-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html?f=22&fvtc=4&fvtv=51595Bionano Announces Presentation of OGM Utility Across Cancer Genomics Research Applications at the American Association for Cancer Research (AACR) Annual Meeting2023-04-13T20:01:00Z<![CDATA[SAN DIEGO, April 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American Association for Cancer Research (AACR) Annual Meeting 2023 with a broad range of content covering the utility of optical genome mapping (OGM) utility for cell bioprocessing quality control, solid tumor and hematological malignancy cancer research. AACR’s annual meeting brings together industry, medical, and academic professionals to discuss advances in cancer science and medicine. The AACR conference will be held April 14-18, 2023, in Orlando, Florida.]]>https://www.globenewswire.com/news-release/2023/04/06/2642516/0/en/Bionano-Announces-Publication-that-Demonstrates-OGM-s-Utility-for-Resolving-Complex-Genetic-Variation-in-Inherited-Retinal-Disease.html?f=22&fvtc=4&fvtv=51595Bionano Announces Publication that Demonstrates OGM’s Utility for Resolving Complex Genetic Variation in Inherited Retinal Disease2023-04-06T12:00:00Z<![CDATA[SAN DIEGO, April 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of a study from researchers at Radboud University Medical Center showing the use of optical genome mapping (OGM) to identify gene disruptive structural variants (SVs) that might contribute to inherited retinal diseases (IRDs). OGM detected a large inversion (173 megabases) impacting the USH2A gene that was initially ignored as a false positive in short-read next-generation sequencing (NGS) data. The authors sought to determine whether OGM could improve SV detection in genetically unexplained IRD cases. Their results identified several pathogenic SVs had been overlooked in their initial genome analyses by NGS. The publication illustrates the potential impact of combining NGS and OGM for more comprehensive variant analysis.]]>https://www.globenewswire.com/news-release/2023/03/22/2632150/0/en/Bionano-Announces-First-Study-Using-OGM-to-Discover-Structural-Variants-with-Potential-Relevance-to-Genetic-Diagnosis-of-MRKH-Syndrome-a-Syndrome-Impacting-Reproductive-System-Deve.html?f=22&fvtc=4&fvtv=51595Bionano Announces First Study Using OGM to Discover Structural Variants with Potential Relevance to Genetic Diagnosis of MRKH Syndrome, a Syndrome Impacting Reproductive System Development in 1 in 4,500 Females2023-03-22T12:00:00Z<![CDATA[SAN DIEGO, March 22, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced the publication of the first study to evaluate optical genome mapping (OGM) as a method to identify rare structural variants (SVs) that might contribute to the development of Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome. MRKH is one of several forms of Müllerian agenesis, a disorder that affects 1 in 4,500 females and impacts patients’ reproductive systems and potential ability to carry a pregnancy. Molecular diagnosis is helpful in determining the best treatment for MRKH, but because genetic causes are largely unknown, research into this prevalent class of disorders is key to enabling effective therapies. In this study, researchers used OGM to analyze MRKH samples to detect a variety of SVs that may be relevant to MRKH’s genetic etiology in a single assay.]]>https://www.globenewswire.com/news-release/2023/03/15/2627600/0/en/Bionano-Laboratories-Expands-its-Clinical-Testing-Menu-with-Launch-of-OGM-Based-Laboratory-Developed-Tests-LDTs-for-Prenatal-and-Postnatal-Analysis.html?f=22&fvtc=4&fvtv=51595Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis2023-03-15T12:00:00Z<![CDATA[SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. These LDTs offer a genome-wide assessment of structural variants (SVs) and provide comprehensive testing for most common and rare chromosomal abnormalities.]]>https://www.globenewswire.com/news-release/2023/03/13/2625650/0/en/Bionano-Announces-Extensive-Lineup-of-Content-at-American-College-of-Medical-Genetics-and-Genomics-ACMG-Annual-Meeting-Featuring-OGM-Utility-Across-a-Broad-Range-of-Research-Applic.html?f=22&fvtc=4&fvtv=51595Bionano Announces Extensive Lineup of Content at American College of Medical Genetics and Genomics (ACMG) Annual Meeting Featuring OGM Utility Across a Broad Range of Research Applications2023-03-13T12:00:00Z<![CDATA[SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Meeting 2023 with a broad range of content covering optical genome mapping’s (OGM) utility for research areas including rare genetic disease and constitutional disorders. ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. The ACMG conference will be held March 14-18, 2023, in Salt Lake City, Utah.]]>